Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | QXL138AM |
Synonyms | |
Therapy Description |
QXL138AM is an immunocytokine comprising an anti-CD138 antibody fused to a masked IFNalpha2a that is unmasked by proteases in the tumor microenvironment, which increases interferon signaling and cytokine release and potentially inhibits growth of CD138-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
QXL138AM | QXL138AM is an immunocytokine comprising an anti-CD138 antibody fused to a masked IFNalpha2a that is unmasked by proteases in the tumor microenvironment, which increases interferon signaling and cytokine release and potentially inhibits growth of CD138-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |